Abstract
Neglected diseases are prevalent in less developed countries and are associated with high levels of mortality and/or morbidity. The drugs used in clinical practice are toxic, reducing patient compliance, and generally do not result in a cure, and there has also been a surge in drug resistance. Additionally, a major challenge in drug treatment lies in reaching the intracellular sites infected by parasites. The development of nanotechnology-based drug delivery systems for drugs intended to treat neglected diseases is a promising avenue because the use of nanocarriers presents the ability to target drugs to the infected cells, and the prolonged drug release profile possible with these systems permits longer contact between the drug and the parasite. This review describes the roles of colloidal drug carriers, such as liposomes, polymeric nanoparticles and solid lipid nanoparticles, in research on optimizing the delivery of antileishmanial, antitrypanosomal, antichagasic and antimalarial agents.
Keywords: Chagas disease, leishmaniasis, liposomes, malaria, nanoparticles, schistosomiasis.
Current Pharmaceutical Design
Title:Nanotechnological Strategies for the Treatment of Neglected Diseases
Volume: 19 Issue: 41
Author(s): Najeh Maissar Khalil, Ana Cristina de Mattos, Talita Cristina Moraes Moreira Carraro, Daniel Brustolin Ludwig and Rubiana Mara Mainardes
Affiliation:
Keywords: Chagas disease, leishmaniasis, liposomes, malaria, nanoparticles, schistosomiasis.
Abstract: Neglected diseases are prevalent in less developed countries and are associated with high levels of mortality and/or morbidity. The drugs used in clinical practice are toxic, reducing patient compliance, and generally do not result in a cure, and there has also been a surge in drug resistance. Additionally, a major challenge in drug treatment lies in reaching the intracellular sites infected by parasites. The development of nanotechnology-based drug delivery systems for drugs intended to treat neglected diseases is a promising avenue because the use of nanocarriers presents the ability to target drugs to the infected cells, and the prolonged drug release profile possible with these systems permits longer contact between the drug and the parasite. This review describes the roles of colloidal drug carriers, such as liposomes, polymeric nanoparticles and solid lipid nanoparticles, in research on optimizing the delivery of antileishmanial, antitrypanosomal, antichagasic and antimalarial agents.
Export Options
About this article
Cite this article as:
Khalil Maissar Najeh, de Mattos Cristina Ana, Moraes Moreira Carraro Cristina Talita, Ludwig Brustolin Daniel and Mainardes Mara Rubiana, Nanotechnological Strategies for the Treatment of Neglected Diseases, Current Pharmaceutical Design 2013; 19 (41) . https://dx.doi.org/10.2174/138161281941131219135458
DOI https://dx.doi.org/10.2174/138161281941131219135458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inherited Muscle Diseases Towards Improvements of the Mouse Model Catalogue
Current Genomics SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
Current Diabetes Reviews [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Editorial (Thematic Issue Title: Myocardial Cell Death: Molecular Mechanisms & Drug Targets)
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure
Current Pharmaceutical Design Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Importance of Lost Minerals in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design The Multiple Electrocardiographic Manifestations of Ventricular Repolarization Memory
Current Cardiology Reviews High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery